5 comments

[ 3.1 ms ] story [ 26.0 ms ] thread
Pretty wild that nVidia/ARM deal or the Microsoft/Activision deal can and will be prevented by anti-competition agencies, but deals like these just fly by without a hitch. It's almost like there aren't any medical patents at all or that the competition in the field is super healthy.
To be fair Pharma is far from being a duopoly right now
Pfizer has signed a definitive agreement to acquire Seagen. The acquisition hasn't closed, and antitrust regulators could impede it.
Smaller biotechnology don't compete with big pharma they collaborate and partner with them every step of the way. They need companies like Pfizer which have the resources and expertise to fund more R&D, complete clinical trials and get drugs approved world wide.
Anti-competition isn't about that relationship, it's about how it changes the playing field between Pfizer and it's competition, MS as a platform holder doesn't compete with Activision the publisher, but Sony competes with MS as a platform holder, and that the deal would harm it's ability to compete with MS.